ADVM Stock Overview
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.74 |
| 52 Week High | US$29.70 |
| 52 Week Low | US$4.61 |
| Beta | 0.90 |
| 1 Month Change | -21.52% |
| 3 Month Change | -31.10% |
| 1 Year Change | -40.00% |
| 3 Year Change | -74.65% |
| 5 Year Change | -95.77% |
| Change since IPO | -98.12% |
Recent News & Updates
Recent updates
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Nov 18We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13
Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31Shareholder Returns
| ADVM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | -3.6% | -2.4% |
| 1Y | -40.0% | -2.6% | 23.4% |
Return vs Industry: ADVM underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: ADVM underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| ADVM volatility | |
|---|---|
| ADVM Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADVM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ADVM's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 121 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. Fundamentals Summary
| ADVM fundamental statistics | |
|---|---|
| Market cap | US$98.60m |
| Earnings (TTM) | -US$94.11m |
| Revenue (TTM) | US$1.00m |
98.6x
P/S Ratio-1.0x
P/E RatioIs ADVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADVM income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$68.22m |
| Gross Profit | -US$67.22m |
| Other Expenses | US$26.89m |
| Earnings | -US$94.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.52 |
| Gross Margin | -6,722.40% |
| Net Profit Margin | -9,411.10% |
| Debt/Equity Ratio | 0% |
How did ADVM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adverum Biotechnologies, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |